Phaseline

Targets › MAPK14

MAPK14 (Mitogen-activated protein kinase 14): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Neurology.

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. (UniProt, Q16539)

Open in Phaseline: the race on MAPK14, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EIP PharmaNeflamapimod
MAP kinase p38 alpha inhibitor
MAPK14Phase 2Nonfluent Variant Primary Progressive Aphasia (nfvPPA); Moderate to Severe Acute Ischaemic Stroke–

Conditions

Nonfluent Variant Primary Progressive Aphasia (nfvPPA) (1) Moderate to Severe Acute Ischaemic Stroke (1)

Modalities

small molecule (1)

Companies

EIP Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.